Article

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

2021-04-11

Abstract excerpt

Safe, economical and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and halt the pandemic. We have constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains two immunodominant peptides screened from receptor-binding doma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fc085452-6cb1-5817-be8b-9f4c9c0ffbae
DOI: 10.1101/2021.04.10.439275

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunityDOI 10.1101/2021.04.10.439275Read

A universal TLR7-nanoparticle adjuvant promotes broad immune responses against heterologous strains of Influenza and SARS-CoV-2Semantic proximity Read

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concernSemantic proximity Read

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopesSemantic proximity Read

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity Read

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read

High efficacy of VLA2001 vaccine against SARS-CoV-2 infection in non-human primatesSemantic proximity Read

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read

The Preclinical Evaluation of Self-Replicating RNA Oral Vaccine to Simultaneously Neutralize Both SARS-CoV-2 Delta and Alpha VariantsSemantic proximity Read

Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell ImmunitySemantic proximity Read

A human-informed multi-patch T-cell vaccine induces broad CD8⁺ immunity and protects against SARS-CoV-2 infectionSemantic proximity Read

Circular RNA Vaccines against SARS-CoV-2 and Emerging VariantsSemantic proximity Read